MLYS Q4 2024 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MLYSMineralys Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$52M

Net Income

-$49M

EPS (Diluted)

$-0.98

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$67M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$206M

Total Liabilities

$15M

Stockholders' Equity

$191M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$52M	-$28M	-86.8%
Net Income	-$49M	-$24M	-100.7%